Hims & Hers Reports Strong 2025 Growth Amid Escalating Regulatory Scrutiny and Patent Lawsuit Over GLP-1 Products
Summary
Hims & Hers Health, Inc. reported significant revenue growth and profitability for fiscal year 2025, driven by personalized offerings and international expansion, but faces a wave of new regulatory investigations and a patent infringement lawsuit concerning its compounded GLP-1 weight loss products.
Key Events
-
Strong 2025 Financial Performance
Revenue increased 59% to $2.35 billion for the year ended December 31, 2025, with net income of $128.4 million and Adjusted EBITDA of $318.0 million, demonstrating continued growth and profitability.
-
Major International Acquisition Announced
The company announced a definitive agreement in February 2026 to acquire Australia-based digital health company Eucalyptus for up to $1.15 billion, significantly expanding its global footprint and market presence.
-
New Share Repurchase Program Authorized
A new $250.0 million share repurchase program was authorized in November 2025, with $225.0 million remaining available as of December 31, 2025, signaling a commitment to shareholder returns.
-
Escalating GLP-1 Regulatory Scrutiny
In February 2026, the company was directly named in an FDA statement indicating intent to restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, and HHS referred the company to the DOJ for investigation into potential Federal Food, Drug, and Cosmetic Act violations.
Analysis
Hims & Hers Health, Inc.'s annual report reveals robust financial performance for 2025, with significant revenue growth and continued profitability. However, the filing also discloses a series of critical and recent regulatory and legal challenges concerning its compounded GLP-1 weight loss products. The direct naming by the FDA in a statement about restricting non-FDA-approved compounded GLP-1 APIs, the referral by HHS to the DOJ for potential violations, an SEC investigation into public statements, and a patent infringement lawsuit from Novo Nordisk collectively represent a substantial threat to a key growth area for the company. These developments introduce significant uncertainty and potential operational disruptions, which could materially impact future financial results and reputation, especially as the stock is currently trading near its 52-week lows. While the company is pursuing strategic acquisitions and share repurchases, the immediate and severe nature of these legal and regulatory headwinds overshadows the positive financial and growth initiatives.
At the time of this filing, HIMS was trading at $15.20 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $15.16 to $70.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.